Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15716160 | 0.92 | RORC (0.39) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL26119262 | 0.86 | USP2 (0.41) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL15335039 | 0.85 | USP2 (0.38) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL21634694 | 0.85 | USP2 (0.45) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL1474959 | 0.84 | USP2 (0.44) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL27143591 | 0.84 | MMP2 (0.38) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL2349284 | 0.82 | APP (0.33) | — | |
| SCHEMBL15368794 | 0.82 | USP2 (0.47) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL5765972 | 0.82 | USP2 (0.42) | GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL29161080 | 0.82 | USP2 (0.42) | GPR119USP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| CN-109641897-B | Bcl-2 selective inhibitors, their preparation and use | 北京赛林泰医药技术有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1630650-A | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2005-06-22 | — | — | CN | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | GPR119 144/4885USP2 792/4885SMN1; SMN2 3383/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | GPR119 192/4885USP2 730/4885SMN1; SMN2 3384/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | GPR119 53/4885USP2 635/4885SMN1; SMN2 3927/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | GPR119 53/4885USP2 635/4885SMN1; SMN2 3927/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | GPR119 53/4885USP2 635/4885SMN1; SMN2 3927/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | GPR119 1520/4885USP2 3522/4885SMN1; SMN2 1325/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | GPR119 53/4885USP2 635/4885SMN1; SMN2 3927/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | GPR119 2649/4885USP2 3639/4885SMN1; SMN2 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.